Physician profile
Scott D Stringer
NPI 1720196611
$11,285.59
in general payments reported to CMS, 2019-2025
39 companies · $2,214 in 2025
The $2,214 reported for 2025 was more than what 97% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,405 · 2020: $519 · 2021: $1,446 · 2022: $1,761 · 2023: $1,019 · 2024: $1,921 · 2025: $2,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,149 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,149.11 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,268.27 | 2019-2025 | Tavneos, Evenity, Krystexxa |
| Janssen Pharmaceuticals, INC | $1,252.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,230.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $900.98 | 2019-2025 | Rinvoq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $886.04 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $636.17 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $481.23 | 2019-2024 | Arexvy, Nucala, Benlysta |
| Novartis Pharmaceuticals Corporation | $459.21 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $381.69 | 2022-2024 | Ingrezza |
| Novo Nordisk INC | $346.98 | 2019-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $327.23 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $318.90 | 2019-2024 | Camzyos |
| Janssen Biotech, INC. | $313.56 | 2019-2025 | Tremfya |
| Corcept Therapeutics | $257.82 | 2024-2025 | Korlym |
| Janssen Scientific Affairs, LLC | $233.84 | 2021-2025 | Tremfya |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Stringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.